Dr Marliese Alexander is Deputy Director of Pharmacy at Peter MacCallum Cancer Centre and Research Fellow in the Sir Peter MacCallum Department of Oncology, the University of Melbourne.
Marliese holds a Bachelor of Pharmacy (hons), Master of Public Health, PhD (cancer associated thrombosis / thoracic cancers / real-world data) and Certificate in Data Science.
Her current research efforts focus on real-world data and personalised (biomarker- / pharmacogenomic-guided) therapeutics for the treatment and supportive care of cancer, and on therapeutics and outcomes for people with thoracic cancers. Marliese sits on Steering/Executive Committees for the AUstralian Registry and biObank of thRAcic cancers (AURORA), Victorian Lung Cancer Registry (VLCR), and Clinical Oncology Society of Australia Cancer Pharmacists Group (COSA-CPG).
Marliese has received research fellowship grant funding from the Peter Mac Foundation, Victorian Cancer Agency, and National Health and Medical Council.
Minister for Health's Award for Excellence in Cancer Care, Team award for development and implementation of Surgical Thromboembolism Prevention Program (2015)
Discovery Partner Fellowship, Peter MacCallum Cancer Centre Foundation (2017)
Lea Medal for emerging female research leader (2018)
Victorian Cancer Agency Early Career Health Services Research Fellowship (2018)
Premier's Awards for Health and Medical Research, Finalist for research program ‘Personalised risk assessment to predict outcomes and direct preventive therapies for patients with lung cancer’ (2019)
National Health and Medical Council Emerging Leadership Level 1 Fellowship (2021)
Dynamic Thromboembolic Risk Modelling to Target Appropriate Preventative Strategies for Patients with Non-Small Cell Lung Cancer - https://pubmed.ncbi.nlm.nih.gov/30625975/
Novel approach to precision medicine for supportive care in cancer, specifically clot prediction/prevention. Led to award for Emerging Female Research Leader and fellowship grants (Discovery Partner Fellowship, VCA early career fellowship, NHMRC EL1) to support associated research including a phase 3 RCT of risk-directed primary clot prevention (ACTRN12618000811202).
Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion Diagnostics - https://pubmed.ncbi.nlm.nih.gov/32627882/
International collaboration with Roche Diagnostics Flatiron US Lung Cancer Cohort demonstrating value of companion diagnostics with potential impact to improve access and insurer reimbursements (presented ASCO 2019 and attracting commentaries in Journal of Clinical Pathways, American Journal of Managed Care and X-mol).
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer - https://pubmed.ncbi.nlm.nih.gov/32087434/
Multicentre collaboration between six Australian hospitals. Led to funding and initiation of Australian prospective ROS1 registry (CIA Alexander 2019) as part of the Australian Registry and Biobank of Thoracic Cancers (AURORA).
EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer - https://pubmed.ncbi.nlm.nih.gov/34127383/
Multicentre collaboration between six Australian hospitals to describe characteristics and outcomes of patients with EGFR ex20-insertions, as part of the Australian Registry and Biobank of Thoracic Cancers (AURORA).
Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma - https://pubmed.ncbi.nlm.nih.gov/32535617/
Collaboration with WEHI laboratory group to present clinical and translational data investigating novel role of existing and low cost medicines to improve efficacy of high cost anti-cancer treatments.